Sales are underway for the first CBD drug approved by the U.S. Food and Drug Administration.
The drug, Epidiolex, treats two rare types of epilepsy and is made from marijuana plants grown in the U.K.
The maker of the medication, GW Pharmaceuticals, has said the tincture would cost about $32,500 a year. U.S. insurance companies have not yet determined whether they’ll cover the medication, though GW Pharmaceuticals has announced it will cover some costs for potential patients who apply to the company.
The DEA decided in September that cannabinoid drugs approved by the FDA and containing no more than 0.1% THC would be classified as Schedule 5 drugs, rather than Schedule 1 drugs.
The change was the first time nonsynthetic cannabis has been cleared for medical use by the U.S. federal government.
GW Pharmaceuticals trades on the Nasdaq as GWPH.
Subscribe to our Newsletter
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers